Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
0.00% $2.20
Last updated: 8 aug 2022 - 0:07
TimeZone: America/New_York
FUNDAMENTALS | |
---|---|
MarketCap: | 154.92 mill |
EPS: | -0.946 |
P/E: | 0.000 |
Earnings Date: | Aug 15, 2022 |
SharesOutstanding: | 70.42 mill |
Avg Daily Volume: | 0.182 mill |
RATING 2022-08-05 |
---|
B+ |
Buy |
RATINGDETAILS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
DISCOUNTED CASH FLOW VALUE |
---|
$5.41 (146.04%) $3.21 |
Date: 2022-08-08 |
Expected Trading Range (DAY) |
---|
$ 2.10 - 2.30 ( +/- 4.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 1 250 | Series A Convertible Preferred Stock |
2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 1 250 | Series A Convertible Preferred Stock |
2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 5 750 000 | Common Stock |
2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 1 250 | Series A Convertible Preferred Stock |
2022-04-08 | Bernstein Karen | Buy | 69 424 | Stock Option (right to buy) |
INSIDER POWER |
---|
94.53 |
Last 100 transactions |
Buy: 15 161 448 | Sell: 34 017 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.20 (0.00% ) |
Volume | 0.0357 mill |
Avg. Vol. | 0.182 mill |
% of Avg. Vol | 19.58 % |
Signal 1: | |
Signal 2: |
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.